Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence

Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence

Background: Success has been reported in PD-1/PD-L1 blockade via pembrolizumab, atezolizumab, or avelumab monotherapy in manifold malignancies including metastatic breast cancer. Due to lack of large-scale study, here we present interim analyses to evaluate the safety and efficacy of these promising...

Full description

Bibliographic Details
Main Authors: Yihang Qi, Lin Zhang, Zhongzhao Wang, Xiangyi Kong, Jie Zhai, Yi Fang, Jing Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Pharmacology
Subjects:
PD-1
PD-L1
immunotherapy
breast cancer
safety
efficacy
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.653521/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.653521/full

Similar Items